MedTrace Logo

Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

NCT00515216 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-01-07

Study results available
· View outcomes & findings →

Summary

This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.

Conditions

  • Stomach Neoplasms
  • Esophageal Neoplasms

Interventions

DRUG

5-fluorouracil

DRUG

Oxaliplatin

DRUG

Leucovorin

Sponsors & Collaborators

  • University of Alabama at Birmingham

    collaborator OTHER

  • University of North Carolina

    collaborator OTHER

  • Washington University School of Medicine

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Albert C. Lockhart, M.D. · Washington University School of Medicine

  • Laura Goff, M.D. · Vanderbilt University Medical Center

  • Richard Goldberg, M.D. · University of North Carolina

  • James Posey, M.D. · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-08-31
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515216 on ClinicalTrials.gov